Note: This document contains side effect information about calcitonin. Some of the dosage forms listed on this page may not apply to the brand name Miacalcin.
Common side effects of Miacalcin include: nausea, vomiting, and inflammation at injection site. Other side effects include: diarrhea, flushing of face and/or neck, flushing of hands and feet, gastrointestinal signs and symptoms, stomach pain, flushing, irritation at injection site, pain at injection site, and swelling at injection site. See below for a comprehensive list of adverse effects.
Applies to calcitonin: injection solution
Other dosage forms:
Along with its needed effects, calcitonin (the active ingredient contained in Miacalcin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking calcitonin:
Incidence not known
Some side effects of calcitonin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
Applies to calcitonin: injectable solution, nasal spray
The most commonly reported adverse effects with use of the injection are nausea, injection site inflammation, and flushing of face or hands; rhinitis, epistaxis, back pain, arthralgia, and headache have been reported with use of the nasal spray.
Very common (10% or more): Nausea (10%)
Common (1% to 10%): Abdominal pain
Frequency not reported: Salty taste, diarrhea
With parenteral use, nausea with or without vomiting appears most frequently upon treatment initiation and tends to decrease or disappear with continued use.
Very common (10% or more): Inflammatory reactions at the site of injection
Frequency not reported: Poor appetite
Postmarketing reports: Hypocalcemia with tetany (muscle cramps, twitching) and seizure activity
Postmarketing reports: Serious hypersensitivity reactions including bronchospasm, swelling of the tongue or throat, anaphylactic shock, and death due to anaphylaxis
Symptoms of nose include: Nasal crusts, dryness, redness or erythema, nasal sores, irritation, itching, thick feeling, soreness, pallor, infection, stenosis, runny/blocked, small wound, bleeding wound, tenderness, uncomfortable feeling, and sore across bridge of nose.
Very common (10% or more): Rhinitis (12%), symptoms of nose (11%)
Common (1% to 10%): Epistaxis, sinusitis, upper respiratory tract infection, bronchospasm
Postmarketing reports: Cough, dyspnea
Frequency not reported: Pedal edema
Postmarketing reports: Edema (facial, peripheral, and generalized), hypertension, chest pain syncope, vasodilation
Common (1% to 10%): Dizziness, paresthesia
Postmarketing reports: Headache, tremor, seizure, loss of taste/smell
Postmarketing reports: Anti-drug antibodies
For those that antibody studies were done, circulating antibodies to calcitonin were found in about 50% of patients with Paget's disease after 2 to 18 months of treatment. Circulating antibodies have also been reported with use of the nasal spray.
Common (1% to 10%): Flushing of hand or face, erythematous rash
Frequency not reported: Skin rashes and pruritus of ear lobes
Postmarketing reports: Urticaria, rash/dermatitis, pruritus, alopecia, increased sweating
Common (1% to 10%): Back pain, arthralgia, arthrosis, myalgia
Postmarketing reports: Musculoskeletal pain
Common (1% to 10%): Lymphadenopathy
Common (1% to 10%): Abnormal lacrimation, conjunctivitis
Frequency not reported: Eye pain
Postmarketing reports: Visual disturbance, visual or hearing impairment, tinnitus
Common (1% to 10%): Depression
Frequency not reported: Nocturia
Postmarketing reports: Polyuria
A meta-analysis of 21 randomized, controlled clinical trials among patients using the nasal spray or an investigational oral formulation found the overall incidence of malignancy in patients receiving this drug was 4.1% (254/6151) compared to 2.9% (137/4732) in placebo. An analyses of just nasal spray trials showed the incidence was similar (4.5% vs 2.3%). Data has shown the increased risk was heavily influenced by a single large 5-year trial. A mechanism for this increased risk has not been identified.
Common (1% to 10%): Malignancy
Common (1% to 10%): Influenza-like symptoms
Frequency not reported: Feverish sensation
Postmarketing reports: Fatigue
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Miacalcin